Navigation Links
Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
Date:5/1/2008

Confirms commitment to accelerating market penetration and revenue growth

SCOTTSDALE, Ariz., May 1 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today that Scott Robey joined the company as Vice President of Marketing. Most recently Mr. Robey served as Senior Director of Marketing at Kinetic Concepts, Inc (KCI) for the V.A.C.(R) Therapy brand, during the time US product sales grew from approximately $70 million in 2000 to almost $1.0 billion in 2007.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

"Scott is a proven leader with a record of successfully developing and executing significant growth strategies. His responsibilities include accelerating market penetration of the Provant Wound Therapy System, and expanding our platform technology into adjacent markets," said Virginia Rybski, Acting President of Regenesis. "Scott complements our senior management team, which has experience in early stage, rapidly developing companies, and management of mid-to-large medical technology organizations."

Mr. Robey is an 18 year marketing veteran. He held marketing positions at KCI, Medtronic, Sulzer Carbomedics, and Burron Medical (B. Braun Medical, Inc). His responsibilities have included product management, new product development and commercialization, branding, clinical education programs, and key opinion leader and society relationship development. Mr. Robey has an M.S. in Management from Purdue University, and a B.S. in Biomedical Engineering from Louisiana Tech University.

About the Provant Wound Therapy System

Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues. We believe Provant is effective, economical, and easy-to-use.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long- term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

Contact:

Regenesis Biomedical, Inc.

Media: Scott Robey, VP Marketing robey@regenesisbiomedical.com

Clinicians: Rick Isenberg, MD, VP Clinical Affairs

isenberg@regenesisbiomedical.com

Investors: Virginia Rybski, Acting President

rybski@regenesisbiomedical.com

http://www.regenesisbiomedical.com

480-970-4970


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
2. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
3. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
4. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
5. LifeNet Health(R) Unveils New Biomedical Spine Implant
6. MIT researcher addresses biomedical engineering challenges
7. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
8. Bookham to Enter Biomedical Illumination Market
9. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
10. New NIST mini-sensor may have biomedical and security applications
11. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)... --  iSpecimen ®, the marketplace for human ... (DPS), a full-service anatomic pathology reference lab serving ... , has joined a program offered by iSpecimen ... to make human biospecimens and associated data available to ... in 2015 as a collaboration between iSpecimen and DHIN, ...
(Date:3/22/2017)... 2017   Boston Biomedical , an industry leader ... target cancer stemness pathways, today announced its Board of ... Chief Executive Officer, effective April 24, 2017. ... , M.D., FACP, who has led Boston Biomedical since ... leadership, Boston Biomedical has grown from a "garage startup" ...
(Date:3/22/2017)... , ... March 21, 2017 , ... ... biologics. To acquire information on the desired increase and/or decrease in antibody-dependent cellular ... for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this demand, ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/27/2017)... Strategic Cyber Ventures , the industry,s first cybersecurity focused ... investment in  Polarity , the first commercial human memory-augmentation ... and is led by cybersecurity veterans Tom Kellermann ... , also a longtime cybersecurity veteran and founder of ... round of funding. This new funding will be used ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):